Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Secondary Progressive Multiple Sclerosis: full-pipeline trial registry
4 of 9 indexed Secondary Progressive Multiple Sclerosis trials are currently recruiting.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Secondary Progressive Multiple Sclerosis: 9 US clinical trials tracked, 4 recruiting.
Secondary Progressive Multiple Sclerosis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 2 of these trials.
Enrollment posture brief
Registry condition secondary-progressive-multiple-sclerosis
OPEN 4 | RECR 44% | LATE 3 | EARLY 2 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Secondary Progressive Multiple Sclerosis lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Secondary Progressive Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Secondary Progressive Multiple Sclerosis is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Secondary Progressive Multiple Sclerosis research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Secondary Progressive Multiple Sclerosis enrolment sits around 100 participants.
Median target enrolment is 100 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.
-
Secondary Progressive Multiple Sclerosis research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA)
NCT07299019
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04047628
Functional Outcomes From Diets in Multiple Sclerosis
University of Alabama at Birmingham
NCT05327322
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Tiziana Life Sciences
NCT06292923
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sanofi
NCT06372145
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
Novartis
NCT06395909
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02330965
Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis
Johns Hopkins University
NCT01647321
Novel Imaging Markers in SPMS
University of Utah
NCT05357833
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Secondary Progressive Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Secondary Progressive Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Secondary Progressive Multiple Sclerosis page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Secondary Progressive Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Secondary Progressive Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Secondary Progressive Multiple Sclerosis condition card totals 9 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.